Phase 2 Non Small Cell Clinical Trials
13 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–13 of 13 trials
Recruiting
Phase 1Phase 2
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Lung CancerMelanomaNon-small Cell Lung Cancer+4 more
Obsidian Therapeutics, Inc.208 enrolled9 locationsNCT06060613
Recruiting
Phase 2
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
Iovance Biotherapeutics, Inc.170 enrolled91 locationsNCT04614103
Recruiting
Phase 2
Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
Lung Cancer - Non Small Cell SquamousLung Cancer - Non Small Cell Non-Squamous
Merus B.V.180 enrolled5 locationsNCT07353957
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Mirati Therapeutics Inc.806 enrolled764 locationsNCT04613596
Recruiting
Phase 1Phase 2
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Cervical CancerUrothelial CarcinomaAdvanced Solid Tumor+3 more
GI Innovation, Inc.317 enrolled8 locationsNCT04977453
Recruiting
Phase 2
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung CancerNSCLCAdvanced Non-Small Cell Lung Cancer+1 more
Virginia Commonwealth University40 enrolled1 locationNCT06731413
Recruiting
Phase 1Phase 2
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
RET-altered Non Small Cell Lung CancerRET-altered Solid Tumors
Taiho Pharmaceutical Co., Ltd.244 enrolled21 locationsNCT04683250
Recruiting
Phase 1Phase 2
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Advanced Solid TumorsAdvanced or Metastatic KRAS-mutant Tumor in Pancreatic AdenocarcinomaAdvanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer+2 more
Auricula Biosciences Inc.110 enrolled4 locationsNCT07148128
Recruiting
Phase 2
Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers
Advanced Breast CancerAdvanced Gastric CancerAdvanced Urothelial Cancer+1 more
UNICANCER400 enrolled1 locationNCT07259226
Recruiting
Phase 2
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Metastatic Non Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center571 enrolled18 locationsNCT04410796
Recruiting
Phase 2
Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study
Advanced Non Small Cell Lung Cancer (NSCLC)Third-line and Beyond TherapyRecurrent or Metastatic Lung Cancer+1 more
Li-kun Chen32 enrolled1 locationNCT06728852
Recruiting
Phase 2
Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer Stage
University of Kansas Medical Center50 enrolled6 locationsNCT04992780
Recruiting
Phase 2
OCEANiC: A Phase II, Open-label, Multi-centre Clinical Trial of Osimertinib With or Without Adjuvant Chemotherapy Guided by Tumour NGS Co-mutation Status and ctDNA Detection in Patients With Stage IIA-IIIA EGFR-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection
EGFR-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection
The University of Sydney100 enrolled11 locationsACTRN12623000552684